A single infusion of zimislecel, an investigational stem cell-based therapy, restored physiologic islet function and ...

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Race Oncology announced the successful and safe dosing of the first patient with a ...

Amidst the evolving landscape of military acquisitions and the Army’s renewed commitment to agile, rapid capability ...

They will be randomised and given either a single dose of the vaccine or a placebo. More than 30 trial sites across dengue ...

The successful completion of two NBD1 Phase 1 trials and being the first company to bring NBD1 compounds into the clinic are important milestones,” said Mike Cloonan, President and Chief ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral ...

Mersana’s ongoing Phase 1 trial of Emi-Le is enrolling TNBC patients who have undergone one to four prior treatments, including at least one topoisomerase-1 inhibitor ADC.

“We are thrilled with the successful completion of the Phase 1 SAD study, which demonstrated the safety and tolerability of TIX100 in humans,” said Dr. Anath Shalev, Founder and Chief ...

Galimedix Therapeutics reported oral GAL-101 completed the single ascending dose part of a phase 1 study. ODs would be able to prescribe GAL-101 anywhere in the U.S. but Delaware and Connecticut.

NEW YORK, May 14, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented ...

Crusoe announced the second phase of construction, which includes six additional buildings, expanding the facility to eight buildings encompassing approximately 4 million square feet and a total power ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants. The historically tight-lipped Amgen execs remain judicious ...